Mylan (MYL) Gets FDA Ok for Generic Prevacid
Up)
Mylan Inc. (Nasdaq: MYL) received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) Capsules, 15 mg and 30 mg. This product is shipping immediately and will be sold under the Mylan Pharmaceuticals brand.
Lansoprazole DR Capsules are the generic version of Tap Pharmaceuticals' proton pump inhibitor Prevacid® DR Capsules.
Lansoprazole DR Capsules are the generic version of Tap Pharmaceuticals' proton pump inhibitor Prevacid® DR Capsules.
You May Also Be Interested In
- Mylan (MYL) Unit Launches Generic Viramune Tabs
- IsoRay (ISR) Says GliaSite System Received CE Mark; to Go On Sale in 31 European Markets
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
